DCommon cold
Not recommended
Common cold
Not recommended
Ergoferon combines antibodies to gamma-interferon, CD4, and histamine in homeopathic dilutions. The manufacturer markets it as an antiviral and immune-modulating remedy for acute respiratory viral infection. No convincing benefit has been shown for this use, and there is no quality evidence base behind it for the common cold or flu. For these infections, supportive care usually helps – rest, fluids, and symptomatic relief for fever and congestion; for influenza, a doctor may prescribe agents with proven antiviral activity when indicated. The substance is harmless in this role, but do not take it instead of treatment with proven benefit, so you do not miss the care you need.
Sources
- Can Respir J: Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial. (2021)
- Int J Infect Dis: A clinical trial lacking a control group. (2019)
- Antivir Ther: Retraction: Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice. (2019)
- Int J Infect Dis: Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. (2016)
ICD-10: J00 · ICD-11: CA00